SRRKScholar Rock Holding Corp
Biological Products, (no Diagnostic Substances)
- Revenue
- $0
- Operating margin
- —
- EBITDA
- −$383M
- 53% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$437M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $19M | $33M | — | — | $0 | |
| Operating income | −$130M | −$134M | −$171M | −$252M | −$385M | 53% |
| Net income | −$132M | −$135M | −$166M | −$246M | −$378M | 54% |
| Operating cash flow | −$127M | −$133M | −$145M | −$201M | −$300M | 49% |
| Capex | $5M | $1M | $71K | $98K | $602K | 514% |
| Stock-based comp | $23M | $28M | $27M | $37M | $76M | 106% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $12M · 6
- Open-market sells, 12 mo
- $0 · 0
- Net
- $12M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 487 | — |
| FY2024 | — | — | 478 | — |
| FY2023 | — | — | 208 | — |